{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-001672","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2025-01-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.619870+00:00","generated_at":"2026-05-27T23:55:10.178272+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Esperion provides FY2025 expense guidance at J.P. Morgan Conference","bullets":["R&D expenses expected $55M to $65M for FY2025.","SG&A expenses expected $160M to $170M for FY2025.","Total operating expenses expected $215M to $235M for FY2025.","Guidance announced at 43rd Annual J.P. Morgan Healthcare Conference on Jan 15, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-001672","json":"https://secwatch.observer/filing/0001628280-25-001672.json","markdown":"https://secwatch.observer/filing/0001628280-25-001672.md","text":"https://secwatch.observer/filing/0001628280-25-001672.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025001672/0001628280-25-001672-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025001672/espr-20250115.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T23:55:10.178272+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}